- Home
- GUTS vs DERM Comparison
GUTS vs DERM Comparison
Compare GUTS & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- DERM
- Stock Information
- Founded
- GUTS 2010
- DERM 2014
- Country
- GUTS United States
- DERM United States
- Employees
- GUTS N/A
- DERM N/A
- Industry
- GUTS
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- DERM Health Care
- Exchange
- GUTS NYSE
- DERM Nasdaq
- Market Cap
- GUTS 110.1M
- DERM 116.8M
- IPO Year
- GUTS 2024
- DERM 2021
- Fundamental
- Price
- GUTS $2.03
- DERM $4.92
- Analyst Decision
- GUTS Buy
- DERM Strong Buy
- Analyst Count
- GUTS 2
- DERM 3
- Target Price
- GUTS $18.00
- DERM $9.50
- AVG Volume (30 Days)
- GUTS 275.0K
- DERM 110.0K
- Earning Date
- GUTS 02-02-2025
- DERM 11-12-2024
- Dividend Yield
- GUTS N/A
- DERM N/A
- EPS Growth
- GUTS N/A
- DERM N/A
- EPS
- GUTS N/A
- DERM N/A
- Revenue
- GUTS $97,000.00
- DERM $57,771,000.00
- Revenue This Year
- GUTS N/A
- DERM N/A
- Revenue Next Year
- GUTS N/A
- DERM $36.49
- P/E Ratio
- GUTS N/A
- DERM N/A
- Revenue Growth
- GUTS N/A
- DERM N/A
- 52 Week Low
- GUTS $1.74
- DERM $2.85
- 52 Week High
- GUTS $14.50
- DERM $8.11
- Technical
- Relative Strength Index (RSI)
- GUTS 43.94
- DERM 37.05
- Support Level
- GUTS $1.99
- DERM $4.75
- Resistance Level
- GUTS $2.58
- DERM $5.19
- Average True Range (ATR)
- GUTS 0.19
- DERM 0.28
- MACD
- GUTS -0.02
- DERM -0.07
- Stochastic Oscillator
- GUTS 13.01
- DERM 5.36
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.